Coherus Biosciences (CHRS) has released an update to notify the public and investors about a regulation fd disclosure.
On January 22, 2024, the Company publicized its entry into a Purchase Agreement, details of which were disclosed in a press release included in the Current Report. The content provided under this report is for informational purposes only and is not intended for legal filing under the Exchange Act of 1934 or the Securities Act of 1933.
For further insights into CHRS stock, check out TipRanks’ Stock Analysis page.